← Eichor
Study identifier: NCT06227728 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.

Condition: Non Small Cell Lung Cancer · Breast Cancer · Colorectal Cancer  ·  Sponsor: Gene Solutions

PhaseN/A
Planned participants50
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Lan NL Tu, PHD  ·  +84888843489  ·  lantu@genesolutions.vn

VAN T Phan, MSc  ·  +84908145990  ·  vanphan@genesolutions.vn

Always discuss trial participation with your own doctor first.

Locations (2)

University of Medicine and Pharmacy at HCMCHo Chi Minh City, Hồ Chí Minh, VietnamRecruiting
Medical Genetics InstituteHo Chi Minh City, VietnamNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06227728